american heart association glp 1 GLP-1 drugs can help you lose weight. They can't do this. A new statement, just published in JAMA, makes a point that doesn't get nearly enough attention in the Glucagon-like peptide 1 receptor agonists:

These medications work by preventing glucose reabsorption in the kidney, leading to the excretion of excess glucose through urine

Future Trials Need Timing, Reperfusion, and Safety Answers Stroke-dedicated trials need to answer 3 questions before the acute-treatment claim becomes credible

Phone Support No phone number found for customer support

Making the GLP-1 Companion free puts that research-backed support within reach of everyone on these medications, not just paying Noom members. GLP-1 medications are intended to be used alongside behavioral support protein guidance, muscle preservation, side-effect management, and habit formation but thats not always easy to deliver inside a routine office visit

GLP-1 Receptor Agonists Obesity Drugs Market Regional Analysis North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, driven by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide Patients and providers in the region increasingly value the superior weight loss efficacy, cardiovascular benefits, and convenience of long-acting GLP-1 drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound), which have become key components in chronic weight and metabolic disorder management This widespread use is further supported by favorable reimbursement policies, high healthcare spending, and a proactive medical community, positioning North America as the leading hub for innovation and growth in the GLP-1 obesity drugs space U.S

Ashley Koff, RD 00:12:03 And maybe they also have, you know, some skin issues or some inflammatory issues